PMID- 20353588
OWN - NLM
STAT- MEDLINE
DCOM- 20100916
LR  - 20211020
IS  - 1471-2466 (Electronic)
IS  - 1471-2466 (Linking)
VI  - 10
DP  - 2010 Mar 30
TI  - No effect of epoprostenol on right ventricular diameter in patients with acute 
      pulmonary embolism: a randomized controlled trial.
PG  - 18
LID - 10.1186/1471-2466-10-18 [doi]
AB  - BACKGROUND: Right ventricular dilatation in the setting of acute pulmonary 
      embolism is associated with an adverse prognosis. Treatment with a pulmonary 
      vasodilator has never been studied systematically. We evaluated the effect of 
      epoprostenol on right ventricular diameter and function in patients with acute 
      pulmonary embolism and right ventricular dilatation. METHODS: In a randomized, 
      single-blind study, 14 patients with acute pulmonary embolism received 
      epoprostenol or placebo infusion for 24 hours on top of conventional treatment. 
      Effects on right ventricular end-diastolic diameter, systolic pulmonary artery 
      pressure, right ventricle fractional area change and tricuspid annular plane 
      systolic excursion were assessed by serial echocardiography. Furthermore Troponin 
      T and NT-proBNP were measured serially. RESULTS: Compared to placebo, 
      epoprostenol was associated with a relative change from baseline in right 
      ventricular end-diastolic diameter of +2% after 2.5 hours and -8% after 24 hours. 
      Epoprostenol did not have a significant effect on systolic pulmonary artery 
      pressure, right ventricular fractional area change and tricuspid annular plane 
      systolic excursion, nor on biochemical parameters. CONCLUSION: In patients with 
      acute pulmonary embolism and right ventricular overload, treatment with 
      epoprostenol did not improve right ventricular dilatation or any other measured 
      variables of right ventricular overload. REGISTRATION: URL: NCT01014156Medical 
      ethical committee: Medisch-ethische toetsingscommissie (METc) from the VUmc (free 
      university medical centre).
FAU - Kooter, Albertus J
AU  - Kooter AJ
AD  - Department of Internal Medicine, VU University Medical Center, Amsterdam, the 
      Netherlands. jkooter@vumc.nl
FAU - Ijzerman, Richard G
AU  - Ijzerman RG
FAU - Kamp, Otto
AU  - Kamp O
FAU - Boonstra, Anco B
AU  - Boonstra AB
FAU - Smulders, Yvo M
AU  - Smulders YM
LA  - eng
SI  - ClinicalTrials.gov/NCT01014156
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20100330
PL  - England
TA  - BMC Pulm Med
JT  - BMC pulmonary medicine
JID - 100968563
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Peptide Fragments)
RN  - 0 (Troponin T)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - DCR9Z582X0 (Epoprostenol)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antihypertensive Agents/adverse effects/*pharmacology
MH  - Blood Pressure/drug effects/physiology
MH  - Echocardiography, Doppler
MH  - Epoprostenol/adverse effects/*pharmacology
MH  - Female
MH  - Heart Ventricles/diagnostic imaging/*drug effects/*pathology
MH  - Humans
MH  - Hypertrophy, Right Ventricular/diagnostic imaging/*pathology/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/blood
MH  - Pulmonary Embolism/diagnostic imaging/*pathology/physiopathology
MH  - Single-Blind Method
MH  - Troponin T/blood
MH  - Ventricular Dysfunction, Right/physiopathology
PMC - PMC2859373
EDAT- 2010/04/01 06:00
MHDA- 2010/09/18 06:00
PMCR- 2010/03/30
CRDT- 2010/04/01 06:00
PHST- 2009/10/05 00:00 [received]
PHST- 2010/03/30 00:00 [accepted]
PHST- 2010/04/01 06:00 [entrez]
PHST- 2010/04/01 06:00 [pubmed]
PHST- 2010/09/18 06:00 [medline]
PHST- 2010/03/30 00:00 [pmc-release]
AID - 1471-2466-10-18 [pii]
AID - 10.1186/1471-2466-10-18 [doi]
PST - epublish
SO  - BMC Pulm Med. 2010 Mar 30;10:18. doi: 10.1186/1471-2466-10-18.